

Special Issue

Dopamine Signaling Pathway in Health and Disease

Message from the Guest Editors

Dopamine is a key neurotransmitter modulating multiple and essential physiological functions of the central nervous system, including motor behavior, affective and emotional states, reward and reinforcement behaviors, and other higher cognitive functions. The four major dopaminergic pathways are the nigrostriatal, the mesocortical, the mesolimbic, and the tuberoinfundibular pathway. Dysfunction in the dopaminergic transmission is recognized as a core alteration in several neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), and addiction. This Special Issue on the "Dopamine Signaling Pathway in Health and Disease" will present a selection of original research papers and reviews concerning the cellular and molecular mechanisms underlying dopaminergic neuromodulation under physiological conditions and in preclinical cellular and animal models of dopaminergic neurodegeneration as well as novel potential pharmacological approaches for dopamine-related disorders.

Guest Editors

Prof. Dr. Floriana Volpicelli

Prof. Dr. Maria Concetta Miniaci

Dr. Luisa Speranza

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/141818

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).